First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Recruiting · NCT05745350 · Registry updated 2025-02-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 2 | 2025-02-11 | NCT05745350 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xiaorong Dong | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Union hospital | Wuhan | China | 1 |